BriaCell Therapeutics Corp logo

BriaCell Therapeutics Corp

FRA:8BT (Canada)   Ordinary Shares - New
€ 0.51 (+1.41%) Sep 12
At Loss
Market Cap:
€ 10.27M ($ 11.39M)
Enterprise V:
€ 9.42M ($ 10.45M)
Volume:
-
Avg Vol (2M):
2.60K
Trade In:

Business Description

Description
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset -0.96
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 27.08
9-Day RSI 35.84
14-Day RSI 39.53
6-1 Month Momentum % -81.99
12-1 Month Momentum % -91.61

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.82
Quick Ratio 0.82
Cash Ratio 0.14

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -180.8
Name Current Vs Industry Vs History
ROA % -30.78
ROIC % -1610.12
3-Year ROIIC % -536.9
ROC (Joel Greenblatt) % -1062.01
ROCE % -205.88

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -0.32
EV-to-Forward-EBIT -0.2
EV-to-EBITDA -0.32
EV-to-FCF -0.35
Earnings Yield (Greenblatt) % -313.74
FCF Yield % -270.86

Financials (Next Earnings Date:2024-12-13 Est.)

FRA:8BT's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

BriaCell Therapeutics Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -1.158
Beta 1.31
Volatility % 61.71
14-Day RSI 39.53
14-Day ATR (€) 0.035471
20-Day SMA (€) 0.58745
12-1 Month Momentum % -91.61
52-Week Range (€) 0.444 - 5.89
Shares Outstanding (Mil) 18.28

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BriaCell Therapeutics Corp Filings

Filing Date Document Date Form
No Filing Data

BriaCell Therapeutics Corp Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

BriaCell Therapeutics Corp Frequently Asked Questions

What is BriaCell Therapeutics Corp(FRA:8BT)'s stock price today?
The current price of FRA:8BT is €0.51. The 52 week high of FRA:8BT is €5.89 and 52 week low is €0.44.
When is next earnings date of BriaCell Therapeutics Corp(FRA:8BT)?
The next earnings date of BriaCell Therapeutics Corp(FRA:8BT) is 2024-12-13 Est..
Does BriaCell Therapeutics Corp(FRA:8BT) pay dividends? If so, how much?
BriaCell Therapeutics Corp(FRA:8BT) does not pay dividend.

Press Release

Subject Date
No Press Release